Key Points
- William Guyer sold 11,767 shares of Corcept on March 20 at an average price of $36.01, a transaction totaling $423,729.67 that left him with 2,231 shares — an 84.06% reduction in his stake.
- Guyer has executed multiple large sales this year (20,000 shares on Jan. 6, 20,000 on Feb. 3, and 8,233 on Mar. 4), indicating substantial insider selling activity that some investors may view negatively, though a separate director reportedly bought 100,000 shares in mid‑March.
- Shares jumped amid a major catalyst — FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer — but the rally is accompanied by sharp volatility, an earnings miss and pending securities‑class‑action lawsuits that pose material risks.
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider William Guyer sold 11,767 shares of Corcept Therapeutics stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $36.01, for a total transaction of $423,729.67. Following the completion of the sale, the insider owned 2,231 shares of the company's stock, valued at $80,338.31. This trade represents a 84.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
William Guyer also recently made the following trade(s):
- On Wednesday, March 4th, William Guyer sold 8,233 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.99, for a total transaction of $296,305.67.
- On Tuesday, February 3rd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $40.87, for a total transaction of $817,400.00.
- On Tuesday, January 6th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.18, for a total transaction of $703,600.00.
Corcept Therapeutics Trading Up 19.7%
NASDAQ CORT opened at $40.47 on Thursday. Corcept Therapeutics Incorporated has a 12 month low of $28.66 and a 12 month high of $117.33. The company has a current ratio of 2.92, a quick ratio of 2.85 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $4.30 billion, a PE ratio of 49.35 and a beta of 0.29. The business's 50-day moving average price is $37.41 and its two-hundred day moving average price is $61.15.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing analysts' consensus estimates of $0.33 by ($0.13). The business had revenue of $202.13 million for the quarter, compared to analyst estimates of $254.94 million. Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The business's revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.26 earnings per share. On average, analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.
More Corcept Therapeutics News
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer — key commercial catalyst and the immediate driver of the rally; approval was completed ahead of schedule and trial data showed a survival benefit. FDA Approves Corcept's Lifyorli (BusinessWire)
- Positive Sentiment: Coverage/analyst support: H.C. Wainwright reiterated a Buy and published a $60 price target (lowered from $67) while calling the early approval and long‑term sales outlook supportive — helps justify upside expectations despite the lower PT. Corcept Wins FDA Approval (TipRanks)
- Positive Sentiment: Insider/director buying noted in mid‑March (100,000 shares) has been cited by market commentary as a confidence signal and likely amplified bullish positioning ahead of the approval. Insider Buy & Catalyst Analysis (QuiverQuant)
- Neutral Sentiment: Trading was temporarily halted earlier today for a LULD pause as the stock moved sharply — a market‑structure response to volatility, not company news. (Trading halt reported in market feeds.)
- Neutral Sentiment: Some outlets reported very large intraday moves (30–48%+ intraday prints) as traders re‑priced the stock on the approval; expect continued volatility and large volume in the near term. Market Reaction Coverage (Reuters)
- Negative Sentiment: Multiple law firms have filed/alerted investors about securities‑class‑action suits alleging prior disclosures and regulatory/patent issues — these lawsuits and related allegations (including references to an FDA rejection and court patent loss in filings) represent material legal and financial risk that could pressure the stock. Hagens Berman Securities Class Action Alert (GlobeNewswire)
- Negative Sentiment: Recent insider selling: a disclosed sale by William Guyer on March 20 reduces insider ownership and may be viewed unfavorably by some investors (though offset by the director buy referenced above). Insider Sale SEC Filing
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on CORT shares. Truist Financial raised Corcept Therapeutics to a "strong-buy" rating in a research report on Wednesday. Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, January 23rd. Weiss Ratings reiterated a "hold (c)" rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. UBS Group assumed coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They issued a "neutral" rating and a $95.00 target price for the company. Finally, HC Wainwright cut their price target on shares of Corcept Therapeutics from $67.00 to $60.00 and set a "buy" rating on the stock in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $76.00.
View Our Latest Stock Report on CORT
Institutional Trading of Corcept Therapeutics
A number of institutional investors have recently added to or reduced their stakes in CORT. Torren Management LLC bought a new stake in shares of Corcept Therapeutics during the fourth quarter valued at about $25,000. Advisory Services Network LLC bought a new position in shares of Corcept Therapeutics in the third quarter valued at approximately $25,000. Clearstead Advisors LLC grew its stake in Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company's stock valued at $26,000 after acquiring an additional 193 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new position in Corcept Therapeutics during the fourth quarter valued at approximately $31,000. Finally, Hantz Financial Services Inc. increased its holdings in Corcept Therapeutics by 113.7% during the 4th quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 524 shares during the period. Hedge funds and other institutional investors own 93.61% of the company's stock.
About Corcept Therapeutics
(
Get Free Report)
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
